CD24 Polymorphism and Acetaminophen Toxicity
CD24 Polymorphism and Acetaminophen Toxicity
批准号:
7832655
负责人:
Pan Zheng
金额:
$49.96万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-08-31
关键词:
AcetaminophenAffectAllelesAreaAutoimmune DiseasesBone MarrowCellsChimera organismCodeDendritic CellsDrug resistanceDrug toxicityGenerationsGenesGeneticGenetic MarkersGenetic ModelsGenetic PolymorphismHospitalizationHumanITGAX geneImmune responseInflammatoryInterleukin-3MusNecrosisOverdosePharmaceutical PreparationsPlanet MarsPrintingProductionRegulationResearchResearch PersonnelResistanceScienceSuicide attemptTestingToxic effectTransgenic Miceacetaminophen overdosebasecytokinedrug metabolismhepatic necrosispublic health relevanceresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Challenge Area of Personalized Drug Response and Toxicity Challenge Topic: 04-GM-101 A. Specific aims It is well established that drug toxicity varied individually. Although some genetic loci have been identified, most of the genetic factors remain to be elusive. Until now, the genetic factors identified are involved in either drug metabolism or in direct toxicity to the target cells. More recently, we identified CD24-Siglec10/G interaction as a key regulator for host response to necrosis induced by acetaminophen, which is (Science. 2009 Mar 5. [Epub ahead of print]PMID: 19264983)the drug that is associated with the most of the drug overdose-induced hospitalization in the West. Based on our extensive studies on CD24 association with multiple autoimmune disease in humans (PNAS 100(25):15041-6; PLOS Genetics, 2007 Apr 6;3(4):e49), we propose here to test if the only known coding CD24 polymorphism would affect host response to acetaminophen by comparing mice with knockin of the two alleles of human CD24 for their resistance to the acetaminophen. In addition, we will develop a genetic model to determine whether the drug resistancy conveyed by CD24 is due to its regulation of production of inflammatory cytokine by hematopoietic cells, especially dendritic cells, either using a lineage-specific deletion of the CD24 gene, generation of bone marrow chimera or transgenic mice expressing CD24 exclusively on CD11c+ cells. Our proposed studies may potentially identify an important genetic marker for personalized drug resistance and elucidate cellular mechanism by which CD24 regulates drug toxicity. This proposal responds to 04-GM-101*, personalized drug response and toxicity. The proposed studies will be carried out by two new postdoctoral researchers and a technician. The studies can be completed within 2 years.
PUBLIC HEALTH RELEVANCE: It is well established that drug toxicity varied individually. We recently identified CD24-Siglec10/G interaction as a key regulator for host response to liver necrosis induced by acetaminophen (Science. 323:1722 2009). Previous research has estimated that there are 60,000 cases of acetaminophen overdose annually, most of which are suicide attempts. Nearly 26,000 are hospitalized each year. Based on our extensive studies on CD24 association with multiple autoimmune disease in humans (PNAS 100:15041, 2003; PLoS Genetics 3:e49, 2007), we propose here to test if the only known coding CD24 polymorphism would affect host response to acetaminophen. We will compare mice with knockin of the two alleles of human CD24 for their resistance to the acetaminophen. We will develop a genetic model to determine whether the drug resistance conveyed by CD24 is due to its regulation of production of inflammatory cytokine by dendritic cells. Our proposed studies may potentially identify an important genetic marker for personalized drug resistance and elucidate cellular mechanism by which CD24 regulates drug toxicity. This proposal responds to 04-GM-101*, personalized drug response and toxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
mTOR, Inflammation and Senescence of Hematopoietic Stem Cells
-
批准号:8735834
-
项目类别:
-
资助金额:$33.89万
-
财政年份:2010
-
负责人:Pan Zheng
-
依托单位:
mTOR, Inflammation and Senescence of Hematopoietic Stem Cells
-
批准号:8039370
-
项目类别:
-
资助金额:$31.71万
-
财政年份:2010
-
负责人:Pan Zheng
-
依托单位:
mTOR, Inflammation and Senescence of Hematopoietic Stem Cells
-
批准号:8312546
-
项目类别:
-
资助金额:$30.64万
-
财政年份:2010
-
负责人:Pan Zheng
-
依托单位:
mTOR, Inflammation and Senescence of Hematopoietic Stem Cells
-
批准号:8149834
-
项目类别:
-
资助金额:$30.64万
-
财政年份:2010
-
负责人:Pan Zheng
-
依托单位:
mTOR, Inflammation and Senescence of Hematopoietic Stem Cells
-
批准号:8521039
-
项目类别:
-
资助金额:$32.03万
-
财政年份:2010
-
负责人:Pan Zheng
-
依托单位:
CD24 Polymorphism and Acetaminophen Toxicity
-
批准号:7937899
-
项目类别:
-
资助金额:$49.89万
-
财政年份:2009
-
负责人:Pan Zheng
-
依托单位:
PROTO ONCOGENE PML AND TUMOR EVASION OF HOST IMMUNITY
-
批准号:6377341
-
项目类别:
-
资助金额:$21.88万
-
财政年份:1999
-
负责人:Pan Zheng
-
依托单位:
PROTO ONCOGENE PML AND TUMOR EVASION OF HOST IMMUNITY
-
批准号:6173619
-
项目类别:
-
资助金额:$21.24万
-
财政年份:1999
-
负责人:Pan Zheng
-
依托单位:
PROTO ONCOGENE PML AND TUMOR EVASION OF HOST IMMUNITY
-
批准号:6514073
-
项目类别:
-
资助金额:$22.54万
-
财政年份:1999
-
负责人:Pan Zheng
-
依托单位:
PROTO ONCOGENE PML AND TUMOR EVASION OF HOST IMMUNITY
-
批准号:2884584
-
项目类别:
-
资助金额:$18.88万
-
财政年份:1999
-
负责人:Pan Zheng
-
依托单位:
海外基金